NASDAQ · IMRX

Immuneering Corporation

Healthcare · Biotechnology

$4.48▲ 0.45% ($0.02)at close

After hours$4.40▼ 1.79%7:30 PM ET

52-week

$3.86$10.08

Market cap

$162.63M

P/E

-4.31

EPS (TTM)

-$0.89

Next earnings

Nov 11, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -84.76%/yr over the past 1 years.

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$4.48

Estimated value / share

Unavailable

Base scenario

USD

Need current revenue and shares outstanding to build the revenue-driven FCFF model.

Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.

Year 1 growth — · Ending margin — · Discount rate 7.75%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 19, 2026, 11:04 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -50.28%FCF (TTM): -10.59%

What changed

The stock fell 50.28% over the last year. Free cash flow declined 10.59% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Free cash flow fell 10.59% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience.

CEOBenjamin J. Zeskind

SectorHealthcare

IndustryBiotechnology

Employees57

IPO dateJul 30, 2021

https://immuneering.com

Market multiples

Forward P/E—

EV/EBITDA-2.98

Enterprise value$164.78M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-52.15%▼9.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$15.50▲245.98%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.29 · Revenue est —

View

NASDAQ · IMRX

Immuneering Corporation

Healthcare · Biotechnology

$4.48▲ 0.45% ($0.02)at close

After hours$4.40▼ 1.79%7:30 PM ET

52-week

$3.86$10.08

Market cap

$162.63M

P/E

-4.31

EPS (TTM)

-$0.89

Next earnings

Nov 11, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -84.76%/yr over the past 1 years.

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$4.48

Estimated value / share

Unavailable

Base scenario

USD

Need current revenue and shares outstanding to build the revenue-driven FCFF model.

Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.

Year 1 growth — · Ending margin — · Discount rate 7.75%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 19, 2026, 11:04 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -50.28%FCF (TTM): -10.59%

What changed

The stock fell 50.28% over the last year. Free cash flow declined 10.59% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Performance

Return analysis

Company profile

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience.

CEOBenjamin J. Zeskind

SectorHealthcare

IndustryBiotechnology

Employees57

IPO dateJul 30, 2021

https://immuneering.com

Market multiples

Forward P/E—

EV/EBITDA-2.98

Enterprise value$164.78M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROE-52.15%▼9.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$15.50▲245.98%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$0.29 · Revenue est —

View